---
document_datetime: 2024-07-25 12:34:17
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vaborem-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: vaborem-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.4150269
conversion_datetime: 2025-12-25 11:57:36.36063
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vaborem

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0027               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)       | 24/07/2024                          |                                             | PL                               |           |
| IB/0026/G            | This was an application for a group of variations. B.II.d.1.d - Change in the specification parameters | 17/05/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | and/or limits of the finished product - Deletion of a non-significant specification parameter A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0025             | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 23/04/2024 | n/a |                                   |
| PSUSA/10727 /202308 | Periodic Safety Update EU Single assessment - meropenem / vaborbactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/04/2024 | n/a | PRAC Recommendation - maintenance |
| IB/0024/G           | This was an application for a group of variations. B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 07/02/2024 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size   |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0022/G | This was an application for a group of variations. B.I.b.z - Change in control of the AS - Other variation B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 05/01/2024 | n/a |
| IB/0021   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 09/11/2023 | n/a |

<div style=\"page-break-after: always\"></div>

| II/0020             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                          | 28/09/2023   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0019              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 25/05/2023   | 24/07/2023 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Vaborem in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                               |
| PSUSA/10727 /202208 | Periodic Safety Update EU Single assessment - meropenem / vaborbactam                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/03/2023   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0018             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                            | 09/12/2022   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0016             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                           | 24/11/2022   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0010/G           | This was an application for a group of variations. A grouped application including 8 type II variations (C.I.4) and 1 type II variation (C.I.13): Update of sections 4.5 and 5.2 of the SmPC based on the results of a series of non-clinical drug-drug interaction studies undertaken with vaborbactam or meropenem. The Package Leaflet has been updated accordingly. In addition, the MAH has submitted non-clinical data on the phototoxicity potential of meropenem from a 3T3 neutral red uptake | 19/05/2022   | 18/11/2022 | SmPC and PL                      | The in vitro studies conducted to assess vaborbactam and meropenem CYP450 enzyme and transporter-mediated interaction potential indicated low potential for PK interactions between vaborbactam and meropenem and other drugs with regards to CYP inhibition and transporters but not for CYP induction. Relevant drug-drug interactions due to CYP3A4 induction by vaborbactam and meropenem cannot be excluded. Vaborbactam and meropenem were identified as OAT3 substrates in the in vitro assay, but no clinically relevant inhibition of OAT3 by vaborbactam and meropenem is |

<div style=\"page-break-after: always\"></div>

|                     | phototoxicity test. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | expected. Vaborem may decrease the efficacy of hormonal contraceptive drugs containing oestrogen and/or progesterone. Women of childbearing potential should be advised to use alternative effective contraceptive methods during treatment with Vaborem and for a period of 28 days after discontinuation of treatment. For more information, please refer to the Summary of Product Characteristics. Regarding the potential phototoxicity of meropenem, the in vitro phototoxicity study is indicative of lack of phototoxicity for this active substance.   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10727 /202108 | Periodic Safety Update EU Single assessment - meropenem / vaborbactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 07/04/2022 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IB/0014 PSUSA/10727   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) Periodic Safety Update EU Single assessment -        | 18/11/2021 30/09/2021   | 18/11/2022 n/a   | The Applicant has taken the opportunity editorial changes in the French, German, Portuguese, Greek, Finnish, Swedish and information and to adjust the numbering module 3.2.P.8.1 and 3.2.P.8.3. PRAC Recommendation - maintenance   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10727 /202008   | Periodic Safety Update EU Single assessment - meropenem / vaborbactam                                                                                                                          | 09/04/2021              | n/a              | PRAC Recommendation - maintenance                                                                                                                                                                                                    |
| IB/0012               | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                         | 30/03/2021              | n/a              |                                                                                                                                                                                                                                      |
| IB/0011               | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                   | 20/01/2021              | n/a              |                                                                                                                                                                                                                                      |
| IB/0008               | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 15/10/2020              | 19/10/2021       |                                                                                                                                                                                                                                      |
| PSUSA/10727 /202002   | Periodic Safety Update EU Single assessment - meropenem / vaborbactam                                                                                                                          | 01/10/2020              | n/a              | Annex and PL PRAC Recommendation - maintenance                                                                                                                                                                                       |
| IB/0007/G             | This was an application for a group of variations.                                                                                                                                             | 23/09/2020              | n/a              |                                                                                                                                                                                                                                      |
|                       | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                 |                         |                  |                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                     | Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                       |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------|
| PSUSA/10727 /201908 | Periodic Safety Update EU Single assessment - meropenem / vaborbactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/03/2020 | n/a        |                       | PRAC Recommendation - maintenance |
| IAIN/0004/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.II.b.2.c.1 - Change to importer, batch release | 07/11/2019 | 27/03/2020 | SmPC, Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a   |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10727 /201902 | Periodic Safety Update EU Single assessment - meropenem / vaborbactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 03/10/2019 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0002   | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs   | 17/04/2019   | 27/03/2020   | SmPC, Labelling and PL   |
|-------------|---------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|
| T/0001      | Transfer of Marketing Authorisation                                                               | 07/01/2019   | 20/02/2019   | SmPC, Labelling and PL   |